Synthaverse S.A.

WAR:SVE Poland Biotechnology
Market Cap
$71.25 Million
zł296.26 Million PLN
Market Cap Rank
#22799 Global
#141 in Poland
Share Price
zł3.91
Change (1 day)
+1.82%
52-Week Range
zł3.53 - zł5.70
All Time High
zł30.00
Categories
Companies in Poland Biotechnology
About

Synthaverse S.A., a pharmaceutical company, manufactures and sells medicinal preparations, medical devices, and laboratory reagents in Poland, rest of the European Union, and internationally. It operates through BCG and Traditional segments. The company offers OnkoBCG 50 and 100, which are oncological immunotherapy products used to treat superficial and non-invasive bladder tumors; GAMMA anty-D 5… Read more

Synthaverse S.A. (SVE) - Net Assets

Latest net assets as of March 2025: zł120.93 Million PLN

Based on the latest financial reports, Synthaverse S.A. (SVE) has net assets worth zł120.93 Million PLN as of March 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł298.65 Million) and total liabilities (zł177.72 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets zł120.93 Million
% of Total Assets 40.49%
Annual Growth Rate 16.65%
5-Year Change 225.61%
10-Year Change 507.23%
Growth Volatility 1292.88

Synthaverse S.A. - Net Assets Trend (2010–2024)

This chart illustrates how Synthaverse S.A.'s net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Synthaverse S.A. (2010–2024)

The table below shows the annual net assets of Synthaverse S.A. from 2010 to 2024.

Year Net Assets Change
2024-12-31 zł121.47 Million +7.84%
2023-12-31 zł112.64 Million +6.71%
2022-12-31 zł105.56 Million +41.59%
2021-12-31 zł74.55 Million +99.84%
2020-12-31 zł37.31 Million +13.51%
2019-12-31 zł32.87 Million +8.12%
2018-12-31 zł30.40 Million -47.41%
2017-12-31 zł57.81 Million +5029.37%
2016-12-31 zł1.13 Million -94.37%
2015-12-31 zł20.00 Million -65.06%
2014-12-31 zł57.25 Million -2.12%
2013-12-31 zł58.49 Million +30.69%
2012-12-31 zł44.75 Million -10.61%
2011-12-31 zł50.06 Million +256.09%
2010-12-31 zł14.06 Million --

Equity Component Analysis

This analysis shows how different components contribute to Synthaverse S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have decreased by 864.6% over the analyzed period, potentially due to dividend distributions or operating losses.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Common Stock zł7.08 Million 5.83%
Other Comprehensive Income zł12.46 Million 10.25%
Other Components zł122.06 Million 100.49%
Total Equity zł121.47 Million 100.00%

Synthaverse S.A. Competitors by Market Cap

The table below lists competitors of Synthaverse S.A. ranked by their market capitalization.

Company Market Cap
Challenger Gold Limited
PINK:CLLEF
 		$35.89 Million
Duksung
KO:004830
 		$35.90 Million
BROOGE ENERGY DL-0001
F:3SF
 		$35.90 Million
SAGA COMMUNICATNS A DL-01
F:SGHB
 		$35.90 Million
Real Consulting S.A.
F:K2Q
 		$35.88 Million
Red Hill Minerals Ltd
AU:RHI
 		$35.87 Million
Onyx Healthcare Inc.
TWO:6569
 		$35.87 Million
Ulusal Faktoring AS
IS:ULUFA
 		$35.82 Million

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Synthaverse S.A.'s equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 112,639,000 to 121,471,000, a change of 8,832,000 (7.8%).
  • Net income of 7,550,000 contributed positively to equity growth.
  • Dividend payments of 2,224,000 reduced retained earnings.
  • Other factors increased equity by 3,506,000.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income zł7.55 Million +6.22%
Dividends Paid zł2.22 Million -1.83%
Other Changes zł3.51 Million +2.89%
Total Change zł- 7.84%

Book Value vs Market Value Analysis

This analysis compares Synthaverse S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 2.27x
  • The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
  • The price-to-book ratio has decreased from 8.83x to 2.27x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
2010-12-31 zł0.44 zł3.91 x
2011-12-31 zł1.30 zł3.91 x
2012-12-31 zł1.16 zł3.91 x
2013-12-31 zł1.52 zł3.91 x
2014-12-31 zł1.31 zł3.91 x
2015-12-31 zł0.45 zł3.91 x
2016-12-31 zł0.03 zł3.91 x
2017-12-31 zł1.01 zł3.91 x
2018-12-31 zł0.50 zł3.91 x
2019-12-31 zł0.53 zł3.91 x
2020-12-31 zł0.60 zł3.91 x
2021-12-31 zł1.18 zł3.91 x
2022-12-31 zł1.61 zł3.91 x
2023-12-31 zł1.60 zł3.91 x
2024-12-31 zł1.72 zł3.91 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Synthaverse S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 6.22%
  • The company has moderate efficiency in generating returns from equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 10.52%
  • • Asset Turnover: 0.24x
  • • Equity Multiplier: 2.46x
  • Recent ROE (6.22%) is above the historical average (-154.80%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
2010 18.07% 8.21% 0.42x 5.23x zł1.13 Million
2011 1.05% 1.34% 0.37x 2.12x zł-4.48 Million
2012 -11.87% -21.55% 0.26x 2.10x zł-9.79 Million
2013 3.99% 7.09% 0.34x 1.67x zł-3.51 Million
2014 0.29% 0.49% 0.30x 1.96x zł-5.56 Million
2015 -186.17% -87.45% 0.26x 8.31x zł-39.24 Million
2016 -2083.05% -64.60% 0.32x 99.96x zł-23.59 Million
2017 1.02% 1.87% 0.26x 2.09x zł-5.19 Million
2018 -106.62% -100.37% 0.37x 2.84x zł-35.45 Million
2019 7.55% 6.35% 0.48x 2.47x zł-803.70K
2020 11.90% 11.05% 0.47x 2.30x zł708.40K
2021 5.70% 10.32% 0.35x 1.57x zł-3.21 Million
2022 5.76% 12.07% 0.31x 1.55x zł-4.47 Million
2023 4.22% 8.12% 0.22x 2.36x zł-6.51 Million
2024 6.22% 10.52% 0.24x 2.46x zł-4.60 Million

Industry Comparison

This section compares Synthaverse S.A.'s net assets metrics with peer companies in the Biotechnology industry.

Industry Context

  • Industry: Biotechnology
  • Average net assets among peers: $85,693,491
  • Average return on equity (ROE) among peers: -48.39%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Synthaverse S.A. (SVE) zł120.93 Million 18.07% 1.47x $35.89 Million
Bioceltix S.A. (BCX) $1.91 Million -83.78% 0.69x $71.31 Million
Bioton S.A. (BIO) $619.64 Million 5.47% 0.40x $42.39 Million
Captor Therapeutics S.A. (CTX) $124.20 Million -26.23% 0.16x $69.93 Million
Mabion S.A. (MAB) $-54.16 Million 0.00% 0.00x $31.56 Million
Molecure S.A. (MOC) $126.45 Million -10.71% 0.09x $21.11 Million
Nanogroup SA (NNG) $8.37 Million -119.60% 1.43x $12.30 Million
Pharmena S.A. (PHR) $8.98 Million -45.66% 0.29x $2.62 Million
PolTREG S.A. (PTG) $12.83 Million -6.84% 0.27x $16.72 Million
Pure Biologics Spólka Akcyjna (PUR) $7.21 Million -65.22% 2.02x $2.90 Million
Ryvu Therapeutics SA (RVU) $1.50 Million -131.36% 5.84x $100.54 Million